Skip to main content
SpringerLink
Log in

Sulfate Homeostasis. III. Effect of Chronic Naproxen or Sulindac Treatment on Inorganic Sulfate Disposition in Arthritic Patients with Renal Impairment

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

The purpose of the present investigation was to examine the influence of chronic naproxen (500 mg twice daily) or sulindac (200 mg twice daily) therapy on the disposition of inorganic sulfate in arthritic subjects with impaired renal function. Subjects were studied during a control period (after a 7-day NSAID washout) and after 14 days of treatment with either naproxen or sulindac. During the control period subjects in this investigation exhibited higher serum sulfate concentrations and lower sulfate renal clearance values than reported for younger subjects with normal renal function. Treatment with either sulindac or naproxen significantly decreased creatinine clearance. Sulindac therapy also increased the serum sulfate concentration and decreased the clearance of sulfate; a similar trend was observed after naproxen therapy but the average change was smaller and not statistically significant. There were significant correlations between the creatinine and the sulfate clearances or serum concentrations. The glomerular filtration rate of inorganic sulfate was not altered by drug treatment and there was no impairment of reabsorption. The serum concentrations and renal clearance of other electrolytes (sodium, potassium, magnesium, calcium, phosphorus) were largely unaffected. Therefore, chronic treatment with naproxen or sulindac decreases the renal clearance of endogenous sulfate in humans: this appears to be a consequence of the decrement in renal function observed in subjects with preexisting mild renal impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. G. J. Mulder. In G. J. Mulder (ed.), Sulfation of Drugs and Related Compounds, CRC Press, Boca Raton, FL, 1981, pp. 131–186.

    Google Scholar 

  2. R. E. Galinsky and G. Levy. J. Pharmacol. Exp. Ther. 219:14–20 (1981).

    Google Scholar 

  3. G. Levy and T. Matsuzawa. J. Pharmacol. Exp. Ther. 156:285–293 (1967).

    Google Scholar 

  4. D. E. Humphries, C. K. Silbert, and J. E. Silbert. J. Biol. Chem. 261:9122–9127 (1986).

    Google Scholar 

  5. B. Tyree, J. R. Hassell, and V. C. Hascall. Arch. Biochem. Biophys. 250:202–210 (1986).

    Google Scholar 

  6. A. Maroudas and H. Evans. Biochim. Biophys. Acta 338:265–279 (1974).

    Google Scholar 

  7. B. J. de Vries, W. B. van den Berg, and L. B. A. van de Putte. Arth. Rheum. 28:922–929 (1985).

    Google Scholar 

  8. P. M. van der Kraan, B. J. de Vries, W. B. van den Berg, E. Vitters, and L. B. A. van de Putte. Agents Actions 23:55–57 (1988).

    Google Scholar 

  9. B. J. de Vries, W. B. van den Berg, E. Vitters, and L. B. A. van de Putte. J. Rheum. 13:686–693 (1986).

    Google Scholar 

  10. E. L. Becker, H. O. Heinemann, K. Igarashi, J. E. Hodler, and H. Gershberg. J. Clin. Invest. 39:1909–1913 (1960).

    Google Scholar 

  11. M. E. Morris and G. Levy. Clin. Pharmacol. Ther. 33:529–536 (1983).

    Google Scholar 

  12. E. Knight, J. Van Wart, and D. A. Roe. J. Nutr. 108:216–225 (1978).

    Google Scholar 

  13. P. K. Halstead and D. A. Roe. Drug-Nutr. Interact. 1:75–86 (1981).

    Google Scholar 

  14. M. E. Morris, O. Kwon, and I. L. Mansfield. J. Pharmacol. Exp. Ther. 244:945–949 (1988).

    Google Scholar 

  15. M. E. Morris and L. J. Benincosa. Pharm. Res. 6(Suppl.):S214 (1989) (abstr.).

    Google Scholar 

  16. H. Bostrom, K. Berntsen, and M. W. Whitehouse. Biochem. Pharmacol. 13:413–420 (1964).

    Google Scholar 

  17. J. H. Herman, A. M. Appel, R. C. Khosla, and E. V. Hess. J. Rheum. 13:1014–1018 (1986).

    Google Scholar 

  18. S. Dekel, J. Falconer, and M. J. O. Francis. Prostaglandins Med. 4:133–140 (1980).

    Google Scholar 

  19. M. J. Palmoski and K. D. Brandt. Arth. Rheum. 23:1010–1020 (1980).

    Google Scholar 

  20. L. S. McKenzie, B. A. Horsburgh, P. Ghosh, and T. K. F. Taylor. Ann. Rheum. Dis. 35:487–497 (1976).

    Google Scholar 

  21. K. D. Brandt and M. J. Palmoski. Am. J. Med. 77:65–69 (1984).

    Google Scholar 

  22. K. H. Lee and M. R. Spencer. J. Pharm. Sci. 58:464–468 (1969).

    Google Scholar 

  23. W. O. Foye, Y.-L. Lai-Chen, and B. R. Patel. J. Pharm. Sci. 70:49–51 (1981).

    Google Scholar 

  24. W. A. Watson, J. P. Freer, and C. Basch. Pharmacotherapy 9:177 (1989) (abstr.).

    Google Scholar 

  25. M. E. Morris and G. Levy. Anal. Biochem. 172:16–21 (1988).

    Google Scholar 

  26. C. H. Fiske and Y. Subbarow. J. Biol. Chem. 66:375–400 (1925).

    Google Scholar 

  27. F. Berglund. Acta Physiol. Scand. 49(Suppl. 172):1–37 (1960).

    Google Scholar 

  28. R. A. Blum and W. A. Watson. Drug Intell. Clin. Pharm. 23:74–75 (1989).

    Google Scholar 

  29. J. W. Rowe, R. Andres, J. D. Tobin, A. H. Norris, and N. W. Shock. J. Gerontol. 31:155–163 (1976).

    Google Scholar 

  30. R. Goldman. In I. Rossman (ed.), Clinical Geriatrics, 2nd ed., J. B. Lippincott, Philadelphia, 1979, pp. 23–59.

    Google Scholar 

  31. R. D. Lindeman, J. Tobin, and N. W. Shock. J. Am. Geriatr. Soc. 33:278–285 (1985).

    Google Scholar 

  32. J. H. Bauer. J. Appl. Physiol. 40:648–650 (1976).

    Google Scholar 

  33. R. J. Ryan, L. R. Pascal, T. Inoye, and L. Bernstein. J. Clin. Invest. 35:1119–1130 (1956).

    Google Scholar 

  34. J. W. Macy. Arch. Int. Med. 54:389–404 (1934).

    Google Scholar 

  35. E. G. Wakefield, M. H. Power, and N. M. Keith. JAMA 97:913–917 (1931).

    Google Scholar 

  36. S. Hänze. Klin. Wochenschr. 21:1247–1251 (1966).

    Google Scholar 

  37. R. M. Freeman and C. J. Richards. Kidney Int. 15:167–175 (1979).

    Google Scholar 

  38. P. Kincaid-Smith. Drugs 32(Suppl. 4):109–128 (1986).

    Google Scholar 

  39. J. H. Bauer, C. S. Brooks, and R. N. Burch. Am. J. Kidney Dis. 2:337–346 (1982).

    Google Scholar 

  40. O. Shemesh, H. Golbetz, J. P. Kriss, and B. D. Myers. Kidney Int. 28:830–838 (1985).

    Google Scholar 

  41. K. J. Berg and T. Talseth. Clin. Pharmacol. Ther. 37:447–452 (1985).

    Google Scholar 

  42. R. D. Toto, S. A. Anderson, D. Brown-Cartwright, J. P. Kokko, and D. C. Brater. Kidney Int. 30:760–768 (1986).

    Google Scholar 

  43. G. Friedlander and C. Amiel. Prostaglandins 29:123–132 (1985).

    Google Scholar 

  44. R. J. Roman, M. Skelton, and C. Lechene. J. Pharmacol. Exp. Ther. 230:295–301 (1984).

    Google Scholar 

  45. S. Garella and R. A. Matarese. Medicine 63:165–181 (1984).

    Google Scholar 

Download references

Author information

Author notes

  1. William A. Watson

    Present address: Department of Emergency Health Services, Truman Medical Center, Kansas City, Missouri

Authors and Affiliations

  1. Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, 527 Hochstetter Hall, Amherst, New York, 14260

    Marilyn E. Morris

  2. Department of Medicine, State University of New York at Buffalo, Buffalo, New York, 14214

    Jack P. Freer

  3. Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, New York

    William A. Watson

Authors
  1. Marilyn E. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jack P. Freer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William A. Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morris, M.E., Freer, J.P. & Watson, W.A. Sulfate Homeostasis. III. Effect of Chronic Naproxen or Sulindac Treatment on Inorganic Sulfate Disposition in Arthritic Patients with Renal Impairment. Pharm Res 8, 242–246 (1991). https://doi.org/10.1023/A:1015856407264

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015856407264

Search

Navigation